Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

First Use Date in General

01^st Nov 2013

First Use Date in Commerce

01^st Nov 2013

Mark Details

Serial Number

No 90266118

Mark Type

No Service/Collective Mark

Attorney Docket Number

44D Filed

44D Current

44E filed

44E Current

66A Filed

66A Current

Current Basis

No Basis

Design Code(s)

05.03.08 -

More than one leaf, including scattered leaves, bunches of leaves not attached to branches

05.03.25 -

Other leaves

26.01.21 -

Circles that are totally or partially shaded

26.11.01 -

Rectangles as carriers or rectangles as single or multiple line borders

26.17.09 -

Curved line(s), band(s) or bar(s)

27.03.04 -

Representations of plants or parts of plants forming letters or numerals, including punctuation

Legal History

Status Date	Action Taken
19^th Dec 2023	REGISTERED-PRINCIPAL REGISTER
19^th Dec 2023	NOTICE OF REGISTRATION CONFIRMATION EMAILED
14^th Nov 2023	NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
13^th Nov 2023	STATEMENT OF USE PROCESSING COMPLETE
13^th Nov 2023	ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08^th Nov 2023	TEAS STATEMENT OF USE RECEIVED
08^th Nov 2023	USE AMENDMENT FILED
02^th May 2023	NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28^th Apr 2023	SOU TEAS EXTENSION RECEIVED
28^th Apr 2023	SOU EXTENSION 4 FILED

TEVA

Classification Information

Class [005]Pharmaceutical Products